274 related articles for article (PubMed ID: 29566385)
1. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.
Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM
Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385
[TBL] [Abstract][Full Text] [Related]
2. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
3. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
5. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
6. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine.
Heverhagen AE; Legrand N; Wagner V; Fendrich V; Bartsch DK; Slater EP
Neuroendocrinology; 2018; 106(4):312-317. PubMed ID: 28848144
[TBL] [Abstract][Full Text] [Related]
8. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
Chen P; Wang Q; Xie J; Kwok HF
Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
[TBL] [Abstract][Full Text] [Related]
9. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
10. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
11. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
12. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.
Miller HC; Frampton AE; Malczewska A; Ottaviani S; Stronach EA; Flora R; Kaemmerer D; Schwach G; Pfragner R; Faiz O; Kos-Kudła B; Hanna GB; Stebbing J; Castellano L; Frilling A
Endocr Relat Cancer; 2016 Sep; 23(9):711-26. PubMed ID: 27353039
[TBL] [Abstract][Full Text] [Related]
14. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival.
Arvidsson Y; Rehammar A; Bergström A; Andersson E; Altiparmak G; Swärd C; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2018 Aug; 31(8):1302-1317. PubMed ID: 29487354
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
[TBL] [Abstract][Full Text] [Related]
18. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
[TBL] [Abstract][Full Text] [Related]
19. [Associated gastroenteropancreatic neuroendocrine tumours to familiar syndromes].
Lecumberri Pascual E
Endocrinol Nutr; 2009 Apr; 56 Suppl 2():10-5. PubMed ID: 19627764
[TBL] [Abstract][Full Text] [Related]
20. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]